P307 HOW AND WHY RHEUMATOLOGISTS PRESCRIBE SYMPTOM-SLOW-ACTING DRUG IN OA? A FRENCH PROSPECTIVE SURVEY  by Dreiser, R.-L. et al.
Osteoarthritis and Cartilage Vol. 14, Supplement B S167
P306 – Table 1. Treatment effect CRx-102 vs placebo ITT
Mean baseline Adjusted mean change Treatment effect (95% CI) p-value
CRx-102 Placebo CRx-102 Placebo
AUSCAN pain 289.4 304.5 -70.9 -20.2 50.8 (8.1, 93.5) 0.010
AUSCAN physical 561.3 610.3 -73.2 -32.6 40.5 (-28.4, 109.5) 0.123
AUSCAN stiffness 61.1 64.5 -15.2 -7.7 7.5 (-1.7, 16.7) 0.054
Joint pain VAS 58.3 62.1 -18.6 -6.3 12.3 (3.0, 21.5) 0.005
Patient global VAS 58.0 62.3 -15.9 -4.2 11.7 (2.5, 20.8) 0.007
Tender joint count 10.5 10.4 -3.7 -2.5 1.2 (-1.0, 3.4) 0.136
Swollen joint count 5.8 5.2 -2.5 -1.5 1.0 (-0.4, 2.4) 0.086
velopment for the treatment of immuno-inflammatory diseases.
Dipyramidole has been shown to selectively amplify the anti-
inflammatory effects of the steroid, without recapitulating the
steroid toxicity. The purpose of this study was to examine the
efficacy and safety of CRx-102 in patients with HOA, dosed with
3 mg prednisolone and 200 mg dipramidole on days 1-7 and 3
mg prednisolone and 400 mg dipyridamole on days 8-42.
Methods: Patients with HOA were enrolled into this randomized
blinded placebo-controlled 42 days study. Eighty-three patients
were enrolled at four centers in Norway, and randomized equally
between placebo and treatment with CRx-102. The majority
(93%) of the patients was female, and the mean age was 60
years. To be eligible patients had to have more than one swollen
and tender joint, a Kellgren-Lawrence (K-L) score of 2 or more
on radiographs, and a score of at least 150 mm pain on the
5x100 mm=500 mm AUSCAN visual analogue scale (VAS). The
primary endpoint was a reduction in pain using the AUSCAN
pain subscale index at Day 42. We also recorded number of PIP,
DIP and CMC joints with tenderness/pain on motion (tender joint
count (TCJ) range (0-20)) and a similar count of joints with soft
tissue swelling (swollen joint count (SJC)). The treatment effect is
presented from ANCOVA analyses adjusted for baseline values
as the difference (with 95% confidence intervals) between the
mean changes from baseline to 42 days with an intention to treat
(ITT) approach where the last post-baseline observation was
carried forward (LOCF) to replace missing values. One-sided
p-values for the differences of least square means adjusted for
baseline are also presented. We also performed per-protocol
(completer) analyses with LOCF.
Results: CRx-102 was statiscally superior to placebo at 42
days for the following endpoints with the ITT analyses: AUSCAN
pain, joint pain VAS, and patient global VAS (Table 1). The
difference for AUSCAN stiffness was borderline significant. With
the completer analyses significant group differences were also
observed for TJC and SJC, and the AUSCAN function subscale
was borderline significant (p=0.08). The overall withdrawal rate
was 22 out of 83 enrolled patients (27%); 6/41 (15%) for placebo
and 16/42 (38%) for active drug. The most frequently reported
adverse event during the study was headache; 52% in the CRx-
102 group compared to 15% in the placebo group. This adverse
event was most frequent during the beginning of dosing, and in
most cases transient.
Conclusions: The novel syncretic drug CRx-102 demonstrated
efficacy in reducing pain in hand OA in this short term study, and
was generally well tolerated. Efficacy was also seen on other
endpoints, including joint counts.
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Purpose: Despite the publication of the European Ligue Against
Rheumatism recommendations for the management of knee and
hip OA, few is known with respect to the way rheumatologists
(RH) really treat their OA patients, and especially prescribe
Symptomatic-slow acting drug in OA (SySADOA), classified in
these guidelines as second line therapy.
Aim of this study: To describe therapeutic uses of French RH
in knee, hip or hand OA regarding SySADOA prescription.
Methods: Cross-sectional pharmaco-epidemiologic study using
a questionnaire. During the last French Congress of Rheumatol-
ogy 500 RH had to answer a questionnaire on their habits re-
garding the use of SySADOA in knee, hip or hand OA. Collected
data: doctor’s characteristics, site of OA treated by SySADOA
and reason for their prescription, co-prescriptions, treatment du-
ration, treatment modality, dosage and route of administration.
Statistics: descriptive: numbers (%) and mean (SD).
Results: 392 rheumatologists answered the questionnaire, of
whom 38% had a private practice, 58% exercised in both hos-
pital and private setting, and 4% only in hospital. They were
aged 47 years, 37% were women, representative of all areas of
France. OA location for which SySADOA is prescribed are (fre-
quency of citations): Knee OA (95%), hip OA (84%), hand OA
including thumb base (66%), and generalized OA (49%). Spine
OA come after in citations. When is the decision taken? When
OA symptoms flare, in association with an NSAID (87%) and/or
a level 1 analgesic (75%). Level 2 analgesics are less associated
(37%). Intra-articular (IA) steroids are associated to SySADOA
in 45% of cases. As co-treatments, weight loss is cited by 65%,
braces by 62% and crutches by 54%. IA hyaluronans injections
are used by 55%, even initiated during a flare. As a long-term
treatment when symptoms are persistent, 97% use SySADOA:
85% in association with a level 1 analgesic. 57% say they often
associate with NSAIDs. 65% then use IA hyaluronans and 83%
prescribe physical therapy. Mean SySADOA treatment duration
reported is 3.8 (4.1) years. For 70% of RH, SySADOA are pre-
scribed more than 3 months, according to a continuous fashion
by 64%, intermit courses for 42%. In this sample, intermittent pre-
scription leaded to an average of 165 (74) days of treatment/year
and 2.4 courses/year (71.5 (37.4) days/course).
Conclusions: In this sample of 392 French RH, SySADOA
appear to be used either during a flare or to treat persistent
chronical symptoms. SySADOA are mostly associated with level
1 analgesics or NSAIDs. Non pharmacological treatments are
less associated. The durations of treatment (administered either
continuously or by course) are very long.
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